Comparative Analysis of the Regulations for the Marketing and Quality Control of Herbal Products Used for Health in France, Peru and West Africa

dc.contributor.authorInes Y. Castro-Dionicio
dc.contributor.authorCharlotte Dumondin
dc.contributor.authorLatifou Lagnika
dc.contributor.authorNicolás Fabre
dc.contributor.authorRokia Sanogo
dc.contributor.authorNoufou Ouédraogo
dc.contributor.authorM Carraz
dc.contributor.authorE.S. Baldé
dc.contributor.authorMadjid Amoussa
dc.contributor.authorBilly Cabanillas
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:29:41Z
dc.date.available2026-03-22T14:29:41Z
dc.date.issued2025
dc.descriptionCitaciones: 1
dc.description.abstractTraditional medicine is increasingly promoted worldwide as a tool to achieve universal access to healthcare. Herbal medicines have formed the basis of healthcare throughout the world and are still widely used, playing a major role in the international health market. However, several factors influence the potential quality of phytotherapy. The diversity of herbal medicines, their various uses and preparation methods, the pluralism in access to these treatments, and the variability in the chemical composition of raw materials depending on their environment are all critical elements. This study compares the regulatory frameworks and quality control practices for plant-based health products in six countries: Benin, Burkina Faso, Guinea, Mali, Peru and France. It also provides an overview of the market in these countries. To do so, we compiled and highlighted key information from WHO guidelines, national legal documents, public databases on product registration and markets, and conducted interviews with health organisation experts. The main findings indicate that West African countries face challenges related to regulatory enforcement and limited industrial and research capacity. In contrast, Peru experienced an initial surge in production following regulation in 1997 and gained international recognition for Amazonian plants, but saw a decline after the 2009 U.S.-Peru Free Trade Agreement due to more stringent standards. France, while notable for its pharmacopoeia, struggles to implement quality control given the high volume of dietary supplements available. Based on these comparative insights, the paper recommends a multidimensional approach: promoting stakeholder training in good practices, developing robust pharmacopoeias, facilitating dialogue between traditional and allopathic medicines, and building shared infrastructures for research and quality control. These strategies, informed by successful practices across countries, aim to support the safe and equitable development of herbal health products worldwide.
dc.identifier.doi10.1111/tmi.70061
dc.identifier.urihttps://doi.org/10.1111/tmi.70061
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/46840
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofTropical Medicine & International Health
dc.sourceNational University of Trujillo
dc.subjectQuality (philosophy)
dc.subjectBusiness
dc.subjectEnforcement
dc.subjectStakeholder
dc.subjectProduct (mathematics)
dc.subjectSustainability
dc.subjectDeveloping country
dc.subjectPublic health
dc.subjectMarketing
dc.subjectHealth care
dc.titleComparative Analysis of the Regulations for the Marketing and Quality Control of Herbal Products Used for Health in France, Peru and West Africa
dc.typearticle

Files